Standard Biotools (LAB) Net Margin (2010 - 2026)

Standard Biotools (LAB) has 17 years of Net Margin data on file, last reported at 670.07% in Q1 2026.

• On a quarterly basis, Net Margin rose 68324.0% year-over-year to 670.07% in Q1 2026; TTM through Mar 2026 was 101.06%, a 14141.0% increase from a year earlier, with the FY2025 full-year figure at 87.77%, up 6271.0% from the prior year.
• Net Margin for Q1 2026 stood at 670.07%, up from 9.12% in the prior quarter.
• Over the last five years, Net Margin for LAB reached as high as 670.07% in Q1 2026 and fell as low as 338.46% in Q2 2022.
• Historically, Net Margin has averaged 10.2% across 5 years, with a median of 70.55% in 2024.
• Across the five-year window, Net Margin tumbled 51684 bps in 2023 and jumped 68324 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 566.95% in 2022, then plunged by 91 bps to 50.11% in 2023, then rose by 12 bps to 56.0% in 2024, then slumped by 116 bps to 9.12% in 2025, then jumped by 7451 bps to 670.07% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 670.07% in Q1 2026, 9.12% in Q4 2025, and 177.41% in Q3 2025.